For research use only. Not for therapeutic Use.
Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities[1][2].
Panaxadiol (1-10 μM, 12 h) inhibits PD-L1 expression in human colon cancer cells[1].
Panaxadiol (1-10 μM, 12 h) inhibits the expression of PD-L1 by suppressing HIF-1α and STAT3 in HCT116 cells[1].
Panaxadiol (oral gavage; 10 or 30 mg/kg; once every 3 days; 30 d) inhibits the growth of HCT116 cells in a xenograft model[1].
| Catalog Number | I002504 |
| CAS Number | 19666-76-3 |
| Synonyms | (3S,5R,8R,9R,10R,12R,13R,14R,17S)-4,4,8,10,14-pentamethyl-17-[(2R)-2,6,6-trimethyloxan-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,12-diol |
| Molecular Formula | C30H52O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H52O3/c1-25(2)13-9-14-30(8,33-25)19-10-16-29(7)24(19)20(31)18-22-27(5)15-12-23(32)26(3,4)21(27)11-17-28(22,29)6/h19-24,31-32H,9-18H2,1-8H3/t19-,20+,21-,22+,23-,24-,27-,28+,29+,30+/m0/s1 |
| InChIKey | PVLHOJXLNBFHDX-XHJPDDKBSA-N |
| SMILES | CC1(CCCC(O1)(C)C2CCC3(C2C(CC4C3(CCC5C4(CCC(C5(C)C)O)C)C)O)C)C |
| Reference | [1]. Wang Z, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1α and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727. [2]. Myong Hak Ri, et al. Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer. J Ethnopharmacol. 2021 Dec 5;281:114370. |
